Precision Biosciences (DTIL) EBT Margin (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly EBT Margin of 79.12% for Q1 2026, up 7327605.0% year-over-year from N/an in Q1 2025, and down 308.17% quarter-over-quarter from 38.01% in Q4 2025.
Precision Biosciences (DTIL) EBT Margin (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported EBT Margin for 9 consecutive years, with 79.12% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 7327605.0% year-over-year to 79.12%; the TTM figure through Mar 2026 stood at 100.7% (up 1475.0% YoY), while the FY2025 annual figure was 563.83%, down 33635.0% from the prior year.
- EBT Margin retreated to 79.12% in Q1 2026 per DTIL's latest filing, from 38.01% in the prior quarter.
- Across five years, EBT Margin topped out at 38.01% in Q4 2025 and bottomed at 212653.85% in Q3 2025.
- Historically, EBT Margin has averaged 24751.09% across 5 years, with a median of 190.59% in 2022.
- Annual changes were most pronounced in 2025 — EBT Margin slumped 20753857 bps — and 2026, when it surged 7327605 bps.
- Precision Biosciences' EBT Margin stood at 102.48% in 2022, then tumbled by 86 bps to 190.93% in 2023, then sank by 1860 bps to 3742.01% in 2024, then jumped by 101 bps to 38.01% in 2025, then slumped by 308 bps to 79.12% in 2026.
- Business Quant data shows DTIL's EBT Margin at 79.12% in Q1 2026, 38.01% in Q4 2025, and 212653.85% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | 12.09% |
| 10 | Precision Biosciences | 232.58 Mn | 145.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79.12% |
| Dec 31, 2025 | 38.01% |
| Sep 30, 2025 | -212,653.85% |
| Jun 30, 2025 | -123,161.11% |
| Mar 31, 2025 | -73,355.17% |
| Dec 31, 2024 | -3,742.01% |
| Sep 30, 2024 | -5,115.28% |
| Jun 30, 2024 | 31.20% |
| Mar 31, 2024 | -17.62% |
| Dec 31, 2023 | -190.93% |
| Sep 30, 2023 | -85.18% |
| Jun 30, 2023 | -38.31% |
| Mar 31, 2023 | -135.34% |
| Dec 31, 2022 | -102.48% |
| Sep 30, 2022 | -190.59% |
| Jun 30, 2022 | -938.82% |
| Mar 31, 2022 | -1,031.93% |
| Dec 31, 2021 | -484.52% |
| Sep 30, 2021 | -92.04% |
| Jun 30, 2021 | 28.41% |